S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
NASDAQ:RKDA

Arcadia Biosciences - RKDA Stock Forecast, Price & News

$0.33
+0.01 (+3.08%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.29
$0.33
50-Day Range
$0.30
$0.56
52-Week Range
$0.29
$2.66
Volume
331,513 shs
Average Volume
945,757 shs
Market Capitalization
$8.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.25

Arcadia Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
872.5% Upside
$3.25 Price Target
Short Interest
Healthy
2.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.70mentions of Arcadia Biosciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.74) to ($0.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

RKDA stock logo

About Arcadia Biosciences (NASDAQ:RKDA) Stock

Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring bath and body care. The company was incorporated in 2002 and is headquartered in Davis, California.

Receive RKDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RKDA Stock News Headlines

StockNews.com Begins Coverage on Arcadia Biosciences (NASDAQ:RKDA)
Arcadia Biosciences (RKDA) Announces CFO Transition
Arcadia Biosciences Inc Stock Quote RKDA
See More Headlines
Receive RKDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RKDA Company Calendar

Last Earnings
11/15/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/29/2023

Industry, Sector and Symbol

Industry
Agricultural production - crops
Sub-Industry
N/A
Current Symbol
NASDAQ:RKDA
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.25
High Stock Price Forecast
$3.50
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+872.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,660,000.00
Net Margins
-183.46%
Pretax Margin
-187.28%

Debt

Sales & Book Value

Annual Sales
$6.78 million
Book Value
$1.41 per share

Miscellaneous

Free Float
24,273,000
Market Cap
$8.24 million
Optionable
Not Optionable
Beta
0.10

Key Executives

  • Ms. Pamela Haley (Age 50)
    CFO & Corp. Sec.
    Comp: $250.08k
  • Ms. Laura Pitlik (Age 48)
    Chief Marketing Officer
    Comp: $160.78k
  • Mr. Stanley E. Jacot Jr. (Age 52)
    Pres, CEO & Director
  • Ms. Belinda Yao
    VP of Operations
  • Mr. Brian Schaffer
    Sr. VP of Sales
  • Mr. Kevin Hodges
    VP of Commercial Operations













RKDA Stock - Frequently Asked Questions

Should I buy or sell Arcadia Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RKDA shares.
View RKDA analyst ratings
or view top-rated stocks.

What is Arcadia Biosciences' stock price forecast for 2023?

1 Wall Street analysts have issued twelve-month target prices for Arcadia Biosciences' stock. Their RKDA share price forecasts range from $3.00 to $3.50. On average, they expect the company's share price to reach $3.25 in the next year. This suggests a possible upside of 872.5% from the stock's current price.
View analysts price targets for RKDA
or view top-rated stocks among Wall Street analysts.

How have RKDA shares performed in 2022?

Arcadia Biosciences' stock was trading at $1.04 on January 1st, 2022. Since then, RKDA shares have decreased by 67.9% and is now trading at $0.3342.
View the best growth stocks for 2022 here
.

When is Arcadia Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our RKDA earnings forecast
.

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences, Inc. (NASDAQ:RKDA) posted its earnings results on Monday, November, 15th. The basic materials company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.13. The basic materials company had revenue of $2.38 million for the quarter, compared to analyst estimates of $2.73 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 73.03% and a negative net margin of 183.46%. During the same quarter in the previous year, the firm earned ($0.54) earnings per share.

When did Arcadia Biosciences' stock split?

Arcadia Biosciences's stock reverse split on the morning of Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO?

1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcadia Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

When did Arcadia Biosciences IPO?

(RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.

What is Arcadia Biosciences' stock symbol?

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Who are Arcadia Biosciences' major shareholders?

Arcadia Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (6.53%) and Vanguard Group Inc. (3.04%). Insiders that own company stock include Pamela Haley and Sarah Reiter.
View institutional ownership trends
.

How do I buy shares of Arcadia Biosciences?

Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcadia Biosciences' stock price today?

One share of RKDA stock can currently be purchased for approximately $0.33.

How much money does Arcadia Biosciences make?

Arcadia Biosciences (NASDAQ:RKDA) has a market capitalization of $8.24 million and generates $6.78 million in revenue each year. The basic materials company earns $-14,660,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.

How can I contact Arcadia Biosciences?

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The official website for the company is www.arcadiabio.com. The basic materials company can be reached via phone at (530) 756-7077, via email at ir@arcadiabio.com, or via fax at 530-756-7027.

This page (NASDAQ:RKDA) was last updated on 12/9/2022 by MarketBeat.com Staff